2014—2016年辽宁省肿瘤医院乳腺癌内分泌治疗药物的使用情况分析  

Analysis on usage of breast cancer endocrine therapy drugs in Liaoning Cancer Hospital and Institute from 2014 to 2016

作　　者：祁英杰[1] 刘广宣[1] QI Ying-jie, LIU Guang-xuan(Department of Pharmacy, Liaoning Cancer Hospital ＆ Institute, Cancer Hospital of China Medical University, Shenyang 110042, Chin)

机构地区：[1]辽宁省肿瘤医院(中国医科大学肿瘤医院)药学部,辽宁沈阳110042

出　　处：《现代药物与临床》2018年第3期681-685,共5页Drugs & Clinic

摘　　要：目的分析2014—2016年辽宁省肿瘤医院乳腺癌内分泌治疗药物的使用情况,为临床合理用药提供参考。方法对2014—2016年辽宁省肿瘤医院乳腺癌内分泌治疗药物的使用金额、用药频度(DDDs)、日均费用(DDC)及药品排序比(B/A)进行统计与分析。结果 2014—2016年乳腺癌内分泌治疗药物的总使用金额和DDDs逐年增长。来曲唑和戈舍瑞林连续3年位列销售金额前两名,来曲唑和他莫昔芬的DDDs始终保持在前两位,其中来曲唑的销售金额和DDDs连续3年居于首位,并呈上升趋势。戈舍瑞林和依西美坦的DDC连续3年居前3位。各种乳腺癌内分泌治疗药物的B/A值为0.5~3.5,其中B/A接近1的药品包括来曲唑、甲羟孕酮和托瑞米芬。结论辽宁省肿瘤医院乳腺癌内分泌治疗药物使用基本合理,符合安全、有效、经济的原则。Objective To analyze the usage of breast cancer endocrine therapy drugs in Liaoning Cancer Hospital and Institute, and to provide reference for rational use in clinic. Methods The utilization information of breast cancer endocrine therapy drugs in Liaoning Cancer Hospital and Institute from 2014 to 2016 was extracted, and the consumption sum, defined daily doses（DDDs）, defined daily cost（DDC）, and drug sequence ratio（B/A） were analyzed statistically. Results From 2014 to 2016, the total consumption sums and DDDs of breast cancer endocrine therapy drugs increased year by year. Consumption sum of letrozole and goserelin ranked the top two for continuous 3 years, and DDDs of letrozole and tamoxifen aways stayed in he top two. Consumption sums and DDDs of letrozole was in the first place persistently, and they had a tendency to rising. DDC of goserelin and exemestane ranked the top three for continuous 3 years. B/A of all breast cancer endocrine therapy drugs were from 0.5 to 3.5. And B/A of letrozole, medroxyprogesterone, and toremifene were close to 1.00. Conclusion The utilization of breast cancer endocrine therapy drugs in Liaoning Cancer Hospital and Institute is reasonable on the whole, according with the principle of safety, effectiveness and economy.

关 键 词：乳腺癌内分泌治疗药物 销售金额 用药频度 日均费用 排序比 

分 类 号：R979.1[医药卫生—药品]